CanadaBis Capital Past Earnings Performance
Past criteria checks 4/6
CanadaBis Capital has been growing earnings at an average annual rate of 63.3%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 54.8% per year. CanadaBis Capital's return on equity is 39.4%, and it has net margins of 15.6%.
Key information
63.3%
Earnings growth rate
65.0%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 54.8% |
Return on equity | 39.4% |
Net Margin | 15.6% |
Last Earnings Update | 31 Jan 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How CanadaBis Capital makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jan 24 | 21 | 3 | 7 | 0 |
31 Oct 23 | 23 | 4 | 7 | 0 |
31 Jul 23 | 22 | 4 | 7 | 0 |
30 Apr 23 | 22 | 4 | 6 | 0 |
31 Jan 23 | 18 | 3 | 5 | 0 |
31 Oct 22 | 15 | 2 | 5 | 0 |
31 Jul 22 | 12 | 1 | 4 | 0 |
30 Apr 22 | 9 | -1 | 5 | 0 |
31 Jan 22 | 8 | -1 | 5 | 0 |
31 Oct 21 | 8 | -2 | 5 | 0 |
31 Jul 21 | 7 | -3 | 4 | 0 |
30 Apr 21 | 9 | -2 | 4 | 0 |
31 Jan 21 | 7 | -2 | 4 | 0 |
31 Oct 20 | 6 | -3 | 4 | 0 |
31 Jul 20 | 4 | -5 | 6 | 0 |
30 Apr 20 | 1 | -10 | 8 | 0 |
31 Jan 20 | 0 | -13 | 8 | 0 |
31 Oct 19 | 0 | -12 | 7 | 0 |
31 Jul 19 | 0 | -9 | 5 | 0 |
30 Apr 19 | 0 | -5 | 1 | 0 |
31 Jan 19 | 0 | -1 | 1 | 0 |
31 Oct 18 | 0 | 0 | 0 | 0 |
31 Jul 18 | 0 | 0 | 0 | 0 |
Quality Earnings: CNAD.F has a high level of non-cash earnings.
Growing Profit Margin: CNAD.F's current net profit margins (15.6%) are higher than last year (14.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CNAD.F has become profitable over the past 5 years, growing earnings by 63.3% per year.
Accelerating Growth: CNAD.F's earnings growth over the past year (25.6%) is below its 5-year average (63.3% per year).
Earnings vs Industry: CNAD.F earnings growth over the past year (25.6%) exceeded the Pharmaceuticals industry 19.9%.
Return on Equity
High ROE: CNAD.F's Return on Equity (39.4%) is considered high.